Pharmaceuticals - Indian - Formulations
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 123.63 | 102.32 | 123.04 | 101.95 | 88.88 |
Total Expenses | 102.95 | 86.43 | 103.48 | 91.16 | 85.97 |
Profit Before Tax | 20.68 | 15.89 | 19.56 | 10.79 | 2.91 |
Profit After Tax | 16.78 | 12.58 | 14.09 | 7.25 | 1.85 |
Operating Profit after Depreciation | 21.04 | 16.11 | 19.78 | 10.86 | 3.10 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 11.47 | 7.04 | 9.32 | 7.21 | 6.41 |
Total Non Current Assets | 21.39 | 18.14 | 17.23 | 19.29 | 25.88 |
Total Current Assets | 160.98 | 149.13 | 138.01 | 121.08 | 95.47 |
TOTAL ASSETS | 182.37 | 167.27 | 155.24 | 140.37 | 121.35 |
Total Shareholder's Fund | 151.91 | 134.58 | 121.73 | 107.64 | 100.37 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 3.65 | 8.90 | 9.94 | -1.71 | 17.78 |
Net Cash used in Investing Activities | -13.34 | 2.13 | -15.61 | 5.86 | -11.16 |
Net Cash used in Financing Activities | 2.58 | -3.79 | 5.44 | 0.19 | -1.35 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 123.61 | 102.36 | 123.06 | 101.96 | 88.94 |
Total Expenses | 102.94 | 86.43 | 103.48 | 91.17 | 83.86 |
Profit Before Tax | 20.67 | 15.93 | 19.58 | 10.79 | 5.08 |
Profit After Tax | 16.78 | 12.62 | 14.13 | 7.26 | 4.08 |
Operating Profit after Depreciation | 21.06 | 16.16 | 19.82 | 10.89 | 5.28 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 11.47 | 7.04 | 9.32 | 7.21 | 6.41 |
Total Non Current Assets | 32.65 | 29.29 | 28.33 | 30.36 | 36.90 |
Total Current Assets | 159.77 | 148.80 | 136.81 | 119.87 | 94.30 |
TOTAL ASSETS | 192.42 | 178.09 | 165.14 | 150.23 | 131.20 |
Total Shareholder's Fund | 161.97 | 145.11 | 131.64 | 117.52 | 110.23 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 3.70 | 10.20 | 2.20 | -1.47 | 17.66 |
Net Cash used in Investing Activities | -12.45 | 1.17 | -15.61 | 5.82 | -11.27 |
Net Cash used in Financing Activities | 2.26 | -3.48 | 5.41 | -0.03 | -1.35 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 24.94 | 21.44 | 23.61 | 27.31 | 32.39 |
Total Expenses | 21.62 | 20.92 | 20.10 | 24.88 | 29.04 |
Profit Before Tax | 9.65 | 5.09 | 6.69 | 5.30 | 5.79 |
Profit After Tax | 7.69 | 5.10 | 3.55 | 4.51 | 5.79 |
Operating Profit after Depreciation | 10.23 | 5.68 | 7.48 | 5.96 | 6.30 |
Particulars (in ₹ Cr.) | 2024-09 | 2024-06 | 2024-03 | 2023-12 | 2023-09 |
---|---|---|---|---|---|
Total Revenue | 24.94 | 21.44 | 23.61 | 27.31 | 32.39 |
Total Expenses | 21.66 | 20.90 | 20.09 | 24.85 | 29.08 |
Profit Before Tax | 9.60 | 5.13 | 6.67 | 5.32 | 5.73 |
Profit After Tax | 7.63 | 5.12 | 3.55 | 4.53 | 5.74 |
Operating Profit after Depreciation | 10.19 | 5.70 | 7.47 | 5.99 | 6.26 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Alpa Laboratories Ltd | ₹115.70 | ₹243.44 |
Sun Pharmaceuticals Industries Ltd | ₹1,745.25 | ₹4,18,743.94 |
Divis Laboratories Ltd | ₹5,733.60 | ₹1,52,209.07 |
Cipla Ltd | ₹1,458.15 | ₹1,17,762.24 |
Torrent Pharmaceuticals Ltd | ₹3,357.15 | ₹1,13,616.11 |
Mankind Pharma Ltd | ₹2,488.40 | ₹1,02,663.15 |
08 Nov 2024, 07:45 pm
27 Sep 2024, 12:15 pm
19 Sep 2024, 10:06 am
05 Aug 2024, 02:29 pm
07 May 2024, 04:32 pm